From kidney to liver: Are sodium–glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers?

doi:10.5527/wjn.121652

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

(11)

(12)

(0)

(11)

(1)

(494)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Sep 25, 2026; 15(3): 121652
Published online Sep 25, 2026. doi: 10.5527/wjn.121652

Full Size Figure Download Figure

Figure 1 PRISMA flow diagram. HCC: Hepatocellular carcinoma.

Citation: Mpisa S, Soldera J. From kidney to liver: Are sodium–glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers? World J Nephrol 2026; 15(3): 121652
URL: https://www.wjgnet.com/2220-6124/full/v15/i3/121652.htm
DOI: https://dx.doi.org/10.5527/wjn.121652

Mpisa S, Soldera J. From kidney to liver: Are sodium–glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers? World J Nephrol 2026; 15(3): 121652 [PMID: 42626005 DOI: 10.5527/wjn.121652]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.